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Growth hormone (GH) resistance is common in uremia and
together with resistance to insulin-like growth factor-1
(IGF-1) contributes to uremic growth retardation and muscle
wasting. Previously, we found decreased GH-stimulated
janus-kinase 2–signal transducers and activators of
transcription 5 (STAT5) phosphorylation and nuclear
translocation in uremia; however, it is unclear whether there
are more distal defects. Therefore, we tested whether the
binding of phosphorylated STAT5b to DNA is intact in
uremia. Using uremic rats we found that in addition to
impaired hepatic STAT5b phosphorylation, the binding of
available phospho-STAT5b to DNA is decreased thus
contributing to impaired IGF-1 gene expression. As sepsis-
induced inflammation causes a loss of body protein and as
Gram-negative infections are relatively common in uremia,
we also characterized mechanisms in which acute
inflammation might contribute to GH resistance in uremia.
Endotoxin-induced inflammation markedly increased the
resistance to GH-mediated STAT5b signaling, and further
decreased STAT5b binding to DNA and IGF-1 gene
expression. These perturbations appear to be related to
increased cytokine expression. Thus, our findings indicate
that hepatic resistance to GH-induced IGF-1 expression in
uremia arises due to defects in STAT5b phosphorylation and
its impaired binding to DNA, processes further aggravated by
inflammation.
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Loss of body protein stores with muscle wasting is a common
and serious complication of acute and chronic renal failure
(CRF) that adversely affects outcome.1,2 Apart from sepsis,
protein energy wasting arises from several processes includ-
ing acidosis, reduced nutrient intake and utilization,
inflammation without sepsis, and resistance to or deficiencies
of anabolic hormones such as growth hormone (GH) and
insulin-like growth factor 1 (IGF-1).3 Resistance to GH is
common in CRF and together with resistance to IGF-1
contributes to growth retardation in children and muscle
wasting in adults.4,5 Usually in adult CRF patients, serum
IGF-1 levels are within the normal range, but are reduced in
those with protein energy wasting, and this has prompted the
use of serum IGF-1 levels as a marker of malnutrition.6 In
acute kidney injury, low serum IGF-1 levels portend an
increase in mortality rate.7
Studies we carried out in rats with CRF indicate that in
liver and skeletal and cardiac muscle resistance to GH arises,
at least in part, due to a defect in GH-stimulated signaling
through the janus-kinase 2 (JAK2)–signal transducers and
activators of transcription 5 (STAT5) pathway, with impaired
stimulation of IGF-1 gene expression, despite intact
GH receptor (GHR) levels8–10. As in these studies there was
evidence of low-grade inflammation, we suggested that the
resistant state may have been caused partly by inflammatory
cytokine activity,8,9 often increased in humans with kidney
failure, especially in those with active sepsis.11 Indeed two
recent studies reported that GH action was impaired in CRF
patients with elevated C-reactive protein levels, but not in
those without inflammation.12,13 Interestingly, in normal
animals and humans inflammation induced by bacterial
sepsis or administration of endotoxin (Escherichia coli
(E. coli)-derived lipopolysaccharide, LPS) also impairs
GH-mediated STAT5 signaling and IGF-1 expression.14–16
This GH-resistant state appears to arise through the release of
proinflammatory cytokines, including tumor necrosis factor
a (TNFa) and interleukin-6 (IL-6).17
Normally, when GH binds to its receptor it activates the
protein-tyrosine kinase JAK2, which phosphorylates the
GHR.4,18 This in turn activates several signaling pathways,
including the STAT pathway. STATs are members of an
http://www.kidney-international.org o r ig ina l a r t i c l e
& 2010 International Society of Nephrology
Received 26 October 2009; revised 1 January 2010; accepted 2 February
2010; published online 7 April 2010
Correspondence: Ralph Rabkin, Department of Medicine, Stanford Uni-
versity, VAPAHCS (111R), 3801 Miranda Avenue, Palo Alto, California 94304,
USA. E-mail: rabkin@stanford.edu
Kidney International (2010) 78, 89–95 89
intracellular protein family that serve both as signaling and
transcription factors. GH stimulates the tyrosine phosphor-
ylation of STAT 1a, 3, 5a, and 5b, which translocate into the
nucleus where they bind to specific DNA sequences and
activate or repress target genes. Among the STAT proteins, it
is STAT5b that has an essential role in GH-induced IGF-1
transcription.19,20 This growth factor mediates many of GH’s
actions and is produced throughout the body, especially in
the liver. Although there is sound evidence that GH-mediated
JAK2/STAT phosphorylation and nuclear translocation is
depressed in uremia,4 it is unclear whether there are more
distal defects in the process in which GH stimulates IGF-1
gene transcription. Accordingly, a major aim of this study,
carried out in rats with CRF, was to determine whether in
addition to impaired GH-mediated STAT5b signaling there is
a more distal defect, namely, depressed STAT5b DNA
binding, which might contribute to the GH-resistant state.
In addition, as sepsis-induced inflammation causes a loss of
body protein stores, which is associated with a poor
outcome,21 and as Gram-negative infections are relatively
common in kidney failure,22 we set out to characterize the
mechanisms in which acute inflammation induced by E. coli-
derived endotoxin, might contribute to the GH-resistant state
in uremia.
RESULTS
Biochemistry
The results from normal saline (NS) and LPS-treated control
(Con) and CRF rats consuming comparable amounts of food
are summarized in Table 1. Subtotal nephrectomy produced a
threefold increase in plasma creatinine and fourfold increase
in blood urea nitrogen levels, whereas weight gain was similar
to that of the controls. LPS did not affect these parameters
over the 4 h study period. Plasma IGF-1 levels were modestly
higher in the NS-treated CRF rats versus the Con-NS group
(Po0.001). In contrast, LPS caused a significant reduction in
IGF-1 levels in both Con and CRF rats.
Hepatic GHR protein levels
There was no statistical differences between the GHR levels in
the four study groups, namely, Con-NS, CRF-NS, Con-LPS,
and CRF-LPS (Figure 1). However, the level in the LPS-CRF
group was 23% lower than in the Con-NS group and this
may conceivably have modestly affected GH signaling.
GH-mediated hepatic phospho-STAT5b signal transduction
STAT5b protein and its phosphorylated form were measured
in whole lysates and nuclear extracts from liver collected
before (t0) and after a bolus of GH (Figures 2a and b).
STAT5b protein levels were similar in all groups. In the
absence of LPS, GH-stimulated STAT5b phosphorylation was
modestly and significantly depressed in CRF and relative
STAT5b phosphorylation (phospho-STAT5b/STAT5b pro-
tein) (Figure 2c), averaged 84±6 and 84±2% of the GH-
treated Con-NS value in whole liver (Po0.05) and nuclear
extracts (Po0.001), respectively. LPS depressed GH-stimu-
lated STAT5b phosphorylation even further in CRF (Figure
2c; Po0.05); relative phosphorylation averaged 41±4 and
45±4% of the Con-NS value in whole liver and nuclear
extracts, respectively. LPS also depressed STAT5b phosphor-
ylation in the Con-LPS group, but to a significantly lesser
extent than in the CRF-LPS group.
GH induced STAT5b binding to DNA
Phospho-STAT5b binding to its specific DNA-binding
sequence was assessed in liver nuclear extracts of the same
animals depicted in Figure 2 by electrophoretic mobility shift
assay (EMSA) using a P32-radiolabeled rat b-casein probe
and a monoclonal antibody directed against STAT5b only.
GH caused a characteristic gel mobility shift complex, and
addition of STAT5b antibody slowed the band mobility,
essentially completely super shifting all DNA-bound radio-
activity (Figure 3a). Of note in CRF, GH-induced STAT5b
DNA-binding activity was reduced, averaging 63±9% of the
Con-NS group value (100±9%, Po0.05, Figure 3b); this
37% decrease of STAT5b DNA-binding activity was sig-
nificantly greater than the 16% decrease in the nuclear
phospho-STAT5b levels described earlier (Figure 2c). LPS
reduced STAT5b DNA binding even further in the CRF rats,
Table 1 | Characteristics of control and CRF rats treated with
saline or endotoxin
Con-NS CRF-NS Con-LPS CRF-LPS
Body weight gain (g) a64±2 a62±6 a64±4 a57±7
Creatinine (mg/dl) a0.4±0.02 b1.2±0.1 a0.4±0.03 b1.4±0.1
BUN (mg/dl) a14±0.6 b60±2.6 a18±2.3 b69±6.7
CO2 (mmol/l)
a25±0.6 a24±0.4 a23±0.5 a23±0.7
IGF-1 (ng/ml) a814±27 b1171±44 c670±25 a,c741±85
Abbreviations: BUN, blood urea nitrogen; CRF, chronic renal failure; IGF-1, insulin-like
growth factor-1; LPS, lipopolysaccharide; NS, normal saline.
Sham-operated control (Con) rats or rats with surgically induced CRF and
comparable food intake were studied after 4 weeks. Four hours before killing, the
animals were treated with NS or LPS. Results mean±s.e.m. of 7–8 rats per group.
Dissimilar superscript letters indicate significant difference between groups in each
row (Po0.05); groups with common superscript letters are similar.
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Figure 1 |Growth hormone receptor (GHR) protein levels are
not statistically altered by CRF and/or lipopolysaccharide
(LPS) treatment. (a) Western immunoblot of basal GHR protein
levels in the liver of Con-NS, CRF-NS, Con-LPS and CRF-LPS rats.
(b) Relative GHR levels corrected for b-actin protein levels in
the same blots, normalized to the control mean level that was
assigned a value of 100.
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to 23±7% of the Con-NS value (Po0.001). A similar
response was evident when LPS was given to Con rats.
Together, these findings indicate that resistance to GH-
induced IGF-1 expression in uremia arises not only because
of a defect in STAT5b phosphorylation, but also because of
impaired binding of STAT5b to DNA. Furthermore, signaling
and DNA binding is worsened by inflammation.
GH stimulated hepatic IGF-1 mRNA
In the absence of LPS, basal IGF-1 mRNA expression did not
differ between the CRF-NS and Con-NS groups (Figure 4).
After GH treatment, IGF-1 mRNA expression increased
significantly in both groups. However, the response in the
CRF-NS group was lower than in the controls (126±21 vs
163±20 relative units, Po0.05). LPS reduced basal IGF-1
expression significantly in both the Con-LPS and CRF-LPS
groups to values B36% lower than in the Con-NS group.
The IGF-1 mRNA response to GH was markedly attenuated
in the Con-LPS rats, whereas in the CRF rats the response
was essentially completely obliterated by LPS. Thus, the
resistance to GH-stimulated IGF-1 gene expression apparent
in CRF was worsened by endotoxin.
Hepatic TNFa and IL-6 mRNA
mRNA levels of the proinflammatory cytokine TNFa were
modestly lower in the CRF-NS group versus the Con-NS
group (Po0.05), whereas the IL-6 levels did not differ
significantly between these two groups (Table 2). LPS
induced a significant, many fold, increase in TNFa and
IL-6 mRNA levels in Con-LPS and CRF-LPS rats, although
the average increase in TNFa expression in the CRF-LPS
group was significantly less than in the CON-LPS group
(Po0.05). Treatment with GH caused a further and
significant increase in TNFa and IL-6 expression in the
Con-LPS-treated rats. Although the average cytokine mRNA
levels did increase after GH treatment in the CRF-LPS group,
the change did not reach statistical significance.
DISCUSSION
We previously reported that in rats with CRF there is a defect
in GH-induced body growth and IGF-1 gene expression in
liver and skeletal muscle that appears to be caused in part, by
impaired GH-stimulated JAK2-STAT signaling with de-
pressed levels of phosphorylated JAK2 and the downstream
phosphorylated STAT5a and 5b proteins.8,9 These latter
proteins mediate both signaling and gene transcription18 and
it has been recently established that it is STAT5b that serves to
stimulate IGF-1 transcription.23 IGF-1 in turn mediates many
of the actions of GH.20 In this study with CRF and sham-
operated control rats consuming comparable amounts of
food, we tested the thesis that in addition to a defect in GH-
stimulated STAT5b phosphorylation and nuclear transloca-
tion, a more distal defect exists, namely, impaired binding of
available phosphorylated STAT5b to DNA. In pursuing this
thesis, we have uncovered a novel defect in the liver of uremic
rats, in which STAT5b binding to DNA is significantly
depressed over and above the depression of STAT5b
phosphorylation, and thus likely contributes to the reduced
GH stimulation of IGF-1 gene expression which we observed.
Although we have uncovered similar abnormalities in acute
inflammation-induced GH signaling and IGF-1 gene expres-
sion which we describe later,15 it is noteworthy that the defect
in GH-mediated JAK2/STAT5 signal transduction present in
uremia is not common to all GH-resistant states. For
example, in the GH-resistant state induced by potassium
depletion, we found that hepatic JAK2/STAT5 signaling is not
depressed and is actually hyper responsive to GH, whereas
STAT5 binding to DNA is unaltered.24 Interestingly, in this
study, serum IGF-1 peptide levels were higher in CRF rats,
despite significantly lower hepatic IGF-1 mRNA levels.
This likely reflects increased trapping of IGF-1 in the
vascular compartment by serum IGF-binding proteins,
which are elevated in CRF and reduce the volume of IGF-1
distribution.25
Recurrent or chronic inflammation is relatively common
in CRF patients for which there are many causes including
bacterial infection.26 Indeed, even before the need for renal
replacement therapy, individuals with CRF are at increased
risk of bacterial infections.27 In those who require main-
tenance dialysis therapy, sepsis is a frequent cause of
hospitalization and is the second leading cause of death.26,28
Infections also occur relatively commonly in the setting of
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Figure 2 |Growth hormone (GH)-stimulated STAT5b protein
tyrosine phosphorylation is impaired in the liver of uremic
rats and is worsened by the administration of endotoxin.
Western immunoblots of phospho-STAT5b and STAT5b protein
levels in (a) whole liver lysates or (b) nuclear extracts from saline
(NS) and lipopolysaccharide (LPS)-treated control (Con) and CRF
rats (6/group). Liver was sampled before (t0) and 15min after
intravenous bolus of GH, 100mg/kg. Pooled Con-NS samples of
liver before and after GH administration were also assayed in
these immunoblots. (c) Relative phosphorylation of STAT5b
protein 15min after a GH bolus in NS- and LPS-treated Con and
CRF animals. Phospho-STAT5b signals were corrected for the
specific protein levels and the ratios were normalized to the
GH-treated Con-NS mean, which was assigned a value of 100. Bars
indicate mean±s.e.m. Dissimilar letters above bars indicate
significant difference between groups (Po0.05); groups with
common letters are similar.
Kidney International (2010) 78, 89–95 91
Y Chen et al.: Growth hormone action in uremia and inflammation o r ig ina l a r t i c l e
acute kidney injury, and the combination of sepsis and acute
kidney injury greatly increases the mortality rate.29 On the
other hand, sepsis is a frequent cause of acute kidney injury
in critically ill patients, especially in those with underlying
CRF.30 In Gram-negative infections, common in renal
patients,22 many of the clinical features arise from the release
of endotoxin, LPS derived from the outer bacterial
membrane, into the circulation.31 This induces a hyper-
catabolic state with increased protein breakdown and
depressed protein synthesis and, if prolonged, significant
protein energy wastage. In critically ill septic patients, high
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Figure 4 |Growth hormone (GH)-induced insulin-like growth
factor-1 (IGF-1) mRNA expression is impaired in liver of
uremic rats and completely suppressed when endotoxemia is
superimposed. Sham-operated control (Con) rats or rats with
surgically induced chronic renal failure (CRF) were given
lipopolysaccharide (LPS) or normal saline (NS) intraperitoneally (IP)
and then were treated with IP recombinant bovine GH, 15min
and again 180min after the LPS or saline treatment. Liver from
rats not treated with GH served as basal controls. Four hours after
the initial LPS or NS administration the liver was collected. mRNA
levels were measured by quantitative real-time PCR and adjusted
for the internal housekeeping gene 18S RNA. The results,
mean±s.e.m. of 8 rats/group, are expressed relative to the control
group assigned a mean value of 100. Dissimilar letters above bars
indicate significant difference between groups (Po0.05); groups
with common letters are similar.
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Figure 3 |Gel mobility shift analysis shows that growth hormone (GH)-induced STAT5b binding to DNA is impaired in liver of CRF
rats and worsened by administration of endotoxin. Nuclear extracts were prepared from liver of rats treated with saline (NS) or
lipopolysaccharide (LPS) 4 h earlier and then killed 15min after receiving intravenous GH, 100 mg/kg. Nuclear STAT5b DNA-binding activity
was assayed with a 32P-labeled b-casein promoter probe in a single gel as detailed in materials and methods section. (a) Distinct STAT5–DNA
complexes (lower arrow) are prominent in the GH-treated rats, and are attenuated in the CRF group and even more so after LPS
administration. An essentially complete supershift (upper arrow) was induced when samples were preincubated with a STAT5b-specific
antibody. (b) STAT5b DNA-binding activity expressed as a percent of the Con-NS value, taken to equal 100. Dissimilar letters above bars
indicate significant difference between groups (Po0.05); groups with common letters are similar.
Table 2 | TNFa and IL-6 mRNA levels in liver of control and
CRF rats and the response to growth hormone and endotoxin
Study groups
GH Con-NS CRF-NS Con-LPS CRF-LPS
TNFa
 a100±10 b63±10 c3476±644 d1702±252
+ a152±45 a,b114±26 e4855±775 d2022±246
IL-6
 a100±27 a117±39 b24,176±7487 b15,344±5628
+ a270±89 a167±53 c41,401±10,221 c,b29,866±8965
Abbreviations: Con, control; CRF, chronic renal failure; GH, growth hormone;
IL-6, interleukin-6; LPS, lipopolysaccharide; NS, normal saline; TNFa, tumor necrosis
factor a.
mRNA levels were measured in the liver of the animals described in Figure 4 by
quantitative real-time PCR and corrected for the internal housekeeping gene 18S
RNA. The results, mean±s.e.m. of 8 rats/group, are expressed relative to the
control group and assigned a mean value of 100. Dissimilar superscript letters
indicate significant difference among groups in each horizontal row and between
GH-treated and untreated groups (Po0.05); groups with common superscript letters
are similar.
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levels of endotoxin have been associated with an increase in
mortality rate, and for this reason the response to
hemoperfusion with polymyxin-B-coated polysterene fibers
to remove the endotoxin has been studied.32 Several small
studies suggest a favorable response, but this needs to be fully
tested. Apart from Gram-negative sepsis as a source of
endotoxin, patients with compromised kidney function may,
to a much lesser extent, be exposed to endotoxin derived
from intestinal bacteria because of compromised intestinal
barrier function.33 Patients requiring hemodialysis may
also be exposed to endotoxin and other bacterial products
through the inadvertent use of contaminated dialysis
solutions.34
Several investigators have shown that inflammation
induced by bacterial sepsis or endotoxin also impairs GH-
stimulated STAT5b signaling and IGF-1 expression in the
liver.14–16 In addition, we reported that endotoxin also
depresses the binding of the available nuclear phosphorylated
STAT5b, to DNA, and together these abnormalities pre-
sumably contribute to the impaired IGF-1 gene transcription.
There is strong evidence indicating that inflammation-
induced GH resistance arises largely because of the release
of proinflammatory cytokines that act in part by increasing
suppressor of cytokine signaling expression.35,36 These
proteins suppress GH signaling by binding to the GHR/
JAK2 complex and inhibiting JAK/STAT phosphorylation. In
some,37,38 but not all, studies,15 hepatic GHR levels were
reported to be reduced and this may also have contributed to
the depressed signaling. As sepsis-induced inflammation
causes a loss of body protein stores and as Gram-negative
infections are relatively common in kidney failure,22 in the
second party of this study, we set out to examine the impact
of superimposed acute inflammation induced by E. coli-
derived endotoxin on hepatic GH signaling and IGF-1 gene
expression in chronic uremia. As anticipated from our earlier
study in rats with normal kidney function,15 endotoxemia
markedly increased the resistance to GH-mediated STAT5b
signaling and DNA binding and IGF-1 gene expression in the
liver of CRF rats. These changes were associated with a
marked increase in TNFa and IL-6 expression, cytokines
produced by hepatocytes and also non-parenchymal liver
cells.39 Interestingly, in those animals not treated with
endotoxin, TNFa and IL-6 mRNA levels were not increased
in the CRF rats. Thus, in this study it does not appear that
underlying chronic inflammation contributed to the GH
resistance observed in the uremic state.
It should be kept in mind that a limitation of this study is
its relatively acute format. Changes in GH signaling and
action were examined after 4 h of inflammation induced by
endotoxin, whereas clinically bacterial infections and expo-
sure to endotoxins are usually far more prolonged. Thus,
extrapolation of our findings to prolonged or chronic
inflammation requires caution and indicates the need for
further study.
In summary, in this study of rats with surgically induced
CRF in which we further explore the mechanism of resistance
to GH-induced IGF-1 gene expression, we found that in liver,
in addition to the known impairment of STAT5b signaling,
there is a more distal defect contributing to the resistant state.
This defect comprises a significant depression of the binding
of available phosphorylated STAT5b to DNA, an essential
requirement for GH-induced initiation of IGF-1 gene
transcription, and likely contributes to protein energy
wasting and growth impairment in uremia. In addition, we
have examined the impact of superimposed acute inflamma-
tion induced by endotoxin on GH signaling and IGF-1 gene
expression in uremia. As anticipated, endotoxemia markedly
increased the resistance to GH-mediated STAT5b signaling
and DNA binding and impaired IGF-1 gene expression, and
this appeared to be related to an increase in proinflammatory
cytokine expression.
MATERIALS AND METHODS
Experimental animals and protocols
Male Sprague–Dawley rats weighing B280 g were studied. CRF was
created by a two-step 5/6 nephrectomy procedure as before.8 Sham-
operated rats served as non-uremic controls (Con) and were food
restricted to an amount equal to the average consumed by the CRF
rats on the previous day. This was done as the GH/IGF-1 system is
nutrient sensitive and impaired when protein and energy intake is
suboptimal.40 After 4 weeks of uremia, inflammation comparable
with that produced by sepsis was induced in half of the CRF and
Con rats by the intraperitoneal injection of E. coli-derived LPS
(L4005, Sigma-Aldrich, St Louis, MO, USA), 1mg/kg. The
remaining CRF and Con rats were treated with NS. Four hours
after LPS or NS administration, the rats were anesthetized and liver
and blood collected. The animal protocols were approved by the
Institutional Animal Care and Use Committee of the Research
Service, Veterans Affairs Palo Alto Health Care System.
GH-activated STAT5b signal transduction and binding to DNA
To study the impact of CRF and endotoxemia on GH-mediated
signal transduction and binding of STAT5b to DNA, Con and CRF
rats were anesthetized 4 h after receiving LPS or NS. The liver was
biopsied by a small incision (basal sample, t0) and then recombinant
bovine GH, 100 mg/kg, (gifted by Monsanto, St Louis, MO, USA)
was injected into the inferior vena cava, and 15min later, the liver
was removed for analysis. Four groups of 7–8 rats each were studied:
Con-NS treated; CRF-NS treated; Con-LPS treated; and CRF-LPS
treated.
GH-stimulated gene expression
As before,15 bovine GH, 3mg/kg was given intraperitoneally, 15min
and again 3 h after the initial injection of LPS or NS, then 1 h later
the liver was harvested. Liver obtained by biopsy from the rats
described in the signaling experiment above served as basal control.
Four groups of rats as above were studied (eight per group).
Assay of mRNA
Exactly as we described before,25 total liver RNA was isolated from
frozen and minced liver and assayed by real-time quantitative PCR
with SYBR green dye as the detection agent using the ABI Prism
7900 Sequence Detection System (Applied Biosystems, Foster City,
CA, USA). Primers for the assay of IGF-1, TNFa, and IL-6, as well as
for the internal control gene, ribosomal 18S, are detailed in an
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earlier publication.15 RNA (1mg) was used for cDNA synthesis with
the iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA,
USA) and the cDNA samples were then subjected to PCR analysis.
Results were quantified using the relative standard curve method.
An internal control gene, 18S RNA, standard curve was also
generated, and the target gene was normalized for this endogenous
control. Each sample was analyzed in triplicate in individual assays
performed on two or more occasions.
Western immunoblotting and immunoprecipitation
The GHR antibody, directed against the full-length of GHR
(B110KD), was gifted by W.R. Baumbach. STAT5b (SC-1656)
and b-actin antibodies (SC-47778) were from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA), and antibody against phosphory-
lated STAT5a/b (Tyr694) was from Cell Signaling Technology
(Danvers, MA, USA). Protein-G agarose was from Millipore
(Temecula, CA, USA). Infrared dye (IRDye) secondary antibodies,
namely, 800CW goat anti-mouse IgG and 680 goat anti-rabbit IgG,
were from LI-COR Biosciences (Lincoln, NE, USA).
Liver lysates and nuclear extracts were prepared and subjected to
immune precipitation with a STAT5b antibody as before.15
Immunoprecipitates were electrophoresed on a 7.5% sodium
dodecyl sulfate-polyacrylamide gel and electroblotted onto nitro-
cellulose membranes. Blots were incubated overnight at 4 1C with
the antibodies against rabbit phospho-STAT5a/b and mouse
monoclonal STAT5b simultaneously. Subsequently, the blots were
incubated with IRDye secondary antibodies, IRDye 800 anti-mouse
(1:2000) and 680-labeled anti-rabbit (1:5000). Blots were scanned
with a Licor Infra-red laser scanner and quantified with the Odyssey
imaging system (LI-COR Biosciences). Relative density units refer to
mean pixel density after local background subtraction. For
measuring the GHR and b-actin levels, liver lysates were subjected
directly to western immunoblot analysis and visualized by the same
method as above.
Electrophoretic shift assay
Electrophoretic mobility shift assay was performed as we detailed
before.15,41 In brief, liver nuclear protein extract, was incubated with
binding buffer and 1 mg of poly(deoxyinosinic-deoxy-cytidylic)
followed by addition of an anti-STAT5b monoclonal antibody.
Thereafter, the double-stranded oligonucleotide probe, which is a
rat b-casein probe15 that is 32P-labeled on one strand using T4
polynucleotide kinase, was added. All four-group samples were
electrophoresed through a single large-size non-denaturing poly-
acrylamide gel, which was then cut in half and the two sections were
simultaneously autoradiographed.
Biochemical assays
Total plasma IGF-1 levels were assayed with an IDS Rat/Mouse
IGF-1 ELISA kit, a two-site immunoenzymometric assay (Immuno-
diagnostic Systems, Fountain Hills, AZ, USA). Plasma creatinine,
urea nitrogen, and CO2 were measured with a Beckman LX 20
Analyzer (Beckman Coulter, Fullerton, CA, USA).
Data analysis and statistics
Phosphorylated protein levels were normalized for the respective
protein levels and the GHR for the actin signal. Specific mRNAs
were normalized for 18S RNA, and are expressed as transcript/
housekeeping gene ratios. The Con-NS-treated group mean was
given a value of 100, and individual values are expressed relative to
this value. Results are the mean±s.e.m. Two-tailed unpaired
Student’s t-tests were used for comparison of two normally
distributed groups. Comparisons between more than two normally
distributed groups were made by one-way analysis of variance
followed by pairwise multiple comparison with the Holms t-test;42
Po0.05 was considered to be significant.
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